Literature DB >> 3128107

Clonal immunoglobulin gene rearrangements in chronic lymphocytic leukemia: a correlative study.

L Soper1, B Bernhardt, A Eisenberg, B Cacciapaglia, L Bennett, A Sanda, M Baird, R Silver, P Benn.   

Abstract

Forty-two patients with chronic lymphocytic leukemia (CLL) were studied for immunoglobulin gene and T-cell receptor gene rearrangements. Immunoglobulin heavy chain gene rearrangements were demonstrable in 41 cases. One rearrangement of the T-cell receptor beta chain gene was detected. Quantification of the relative intensities of germline and rearranged DNA bands suggests that a significant component of the lymphocytosis may be due to cell populations other than the malignant clonal population, particularly in earlier stages of the disease. A direct relationship was found between severity of disease and the relative amount of clonal immunoglobulin heavy chain gene rearrangement. Preliminary data for 12 patients followed sequentially indicated that clinical deteriorations or improvements are reflected in an increase or decrease, respectively, in the proportion of cells with rearranged immunoglobulin genes. Change in the relative proportion of cells with germline versus rearranged genes may provide an additional useful criterion for staging CLL, for more precisely defining the abnormal lymphocyte population, and for monitoring progression of the disease and efficacy of treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128107     DOI: 10.1002/ajh.2830270406

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  2 in total

Review 1.  Clinical experience with fludarabine in leukaemia.

Authors:  M J Keating; E Estey; S O'Brien; H Kantarjian; L E Robertson; W Plunkett
Journal:  Drugs       Date:  1994       Impact factor: 9.546

2.  Genes for interleukin 7 are transcribed in leukemic cell subsets of individuals with chronic lymphocytic leukemia.

Authors:  J Frishman; B Long; W Knospe; S Gregory; J Plate
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.